Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remifentanil Ce for Emergence Cough (Sugammadex vs Neostigmine)
NCT03583021Completed
- Sponsor
- Ajou University School of Medicine
- Start
- Jun 2018
- Primary completion
- Oct 2018
- Modality
- Biodegradable Polymers, Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of Sugammadex, sponsored by Ajou University School of Medicine. Primary endpoint: Optimal effect-site concentration of remifentanil. Started Jun 2018; status: completed.
02
Drugs
Sugammadex
Beyond the preview
Go deeper on NCT03583021.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03583021.